Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Ashish Kacholia-backed smallcap stock soars 17% as board to mull bonus issue, stock split on Sept 27. Do you own ?
25/09/2025
Earnings revival could bring foreign investors back : Mayuresh Joshi
25/09/2025
Ganesh Infraworld plans Rs 200–250 crore share sale
25/09/2025
SBI could receive $466 million in passive inflows if FII limit is raised
25/09/2025
Hindustan Copper shares rally over 6% on surge in global copper prices
25/09/2025
Sebi hasn’t started consultation process to remove weekly expiry, says Nithin Kamath
25/09/2025
